Krystal Biotech Q2 2026: Solid Growth, Strong Cash, But Revenue Shortfall Triggers Sell-Off

Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.